Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease

(2017) Orlaith B. Kelly et al.   INFLAMMATORY BOWEL DISEASES

Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories

(2017) L. I. Bader et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis

(2017) Karoline Freeman et al.   BMJ Open

Clinical performance of an infliximab rapid quantification assay

(2017) Fernando Magro et al.   Therapeutic Advances in Gastroenterology

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

(2016) J. Afonso et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?

(2016) Jean-Francois Jourdil et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients

(2016) Jiadi Lu et al.   BIOSENSORS & BIOELECTRONICS

Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling

(2016) Karoline Freeman et al.   HEALTH TECHNOLOGY ASSESSMENT

A Systematic Review on Infliximab and Adalimumab Drug Monitoring

(2016) Filipa Silva-Ferreira et al.   INFLAMMATORY BOWEL DISEASES

Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease

(2016) Yana Davidov et al.   Journal of Crohns & Colitis

Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease

(2016) Clare Moore et al.   Journal of Crohns & Colitis

Comparison of infliximab drug measurement across three commercially available ELISA kits

(2016) Monique Wei Meng Lee et al.   PATHOLOGY

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

(2016) Aurélien Amiot et al.   Clinics and Research in Hepatology and Gastroenterology

Development and Validation of LC–MS/MS Method for the Quantitation of Infliximab in Human Serum

(2015) Xiaoyun Peng et al.   CHROMATOGRAPHIA

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease

(2015) C. Steenholdt et al.   Journal of Crohns & Colitis

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

(2015) X. Roblin et al.   Journal of Crohns & Colitis

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Anti-TNF therapy: past, present and future

(2014) C. Monaco et al.   INTERNATIONAL IMMUNOLOGY

Tailoring anti-TNF therapy in IBD: drug levels and disease activity

(2014) Shomron Ben-Horin et al.   Nature Reviews Gastroenterology & Hepatology

Letter: dry blood spots for anti-TNF treatment monitoring in IBD

(2013) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

(2013) C L M Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease

(2013) Casper Steenholdt et al.   THERAPEUTIC DRUG MONITORING

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

(2012) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

TNF-  antagonists beyond approved indications: stories of success and prospects for the future

(2010) M. P. Karampetsou et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY